27-Feb-2026
Insiders Quietly Double Down on AbCellera Biologics in Bold Buying Spree
TipRanks (Fri, 27-Feb 9:07 PM ET)
TipRanks (Thu, 26-Feb 10:00 AM ET)
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks
TipRanks (Thu, 26-Feb 1:00 AM ET)
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts
TipRanks (Wed, 25-Feb 7:26 PM ET)
AbCellera Biologics (ABCL) Receives a Buy from Stifel Nicolaus
TipRanks (Wed, 25-Feb 8:46 AM ET)
BMO Capital Remains a Buy on AbCellera Biologics (ABCL)
TipRanks (Wed, 25-Feb 7:40 AM ET)
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Benzinga (Wed, 25-Feb 4:22 AM ET)
What Sparked AbCellera Biologics To Soar Over 9% After Hours
Benzinga (Wed, 25-Feb 3:51 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), AbCellera Biologics (ABCL)
TipRanks (Tue, 24-Feb 9:20 PM ET)
AbCellera Biologics GAAP EPS of -$0.49 beats by $0.15, revenue of $75.1M beats by $38.81M
Seeking Alpha News (Tue, 24-Feb 4:12 PM ET)
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of February 27, 2026, ABCL stock price climbed to $3.61 with 4,973,387 million shares trading.
ABCL has a beta of 1.98, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.17 to the broad based SPY ETF.
ABCL has a market cap of $1.08 billion. This is considered a Small Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $45 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $38 million and exceeded earnings estimates by $.15.
In the last 3 years, ABCL traded as high as $8.63 and as low as $1.89.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IBB, SPDW, IDNA, GWX, ONEQ.
ABCL has outperformed the market in the last year with a price return of +23.6% while the SPY ETF gained +18.5%. However, in the short term, ABCL had mixed performance relative to the market. It has underperformed in the last 3 months, returning -0.8% vs +1.2% return in SPY. But in the last 2 weeks, ABCL shares have fared better than the market returning +16.5% compared to SPY +0.6%.
ABCL support price is $3.38 and resistance is $3.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.